National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 8) (No. PB 62 of 2014)

Overview

The National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 8) (PB 62 of 2014) is an amendment to the National Health Act 1953, which establishes the legislative basis for the Pharmaceutical Benefits Scheme (PBS) under which the Commonwealth provides access to a range of medicines for Australians. The amendment was introduced to update the conditions for payments made under the PBS by removing certain drugs from the list of subsidised pharmaceutical benefits. The objective of the amendment is to ensure that the scheme remains current and effective in meeting the health needs of the population, as determined by the Pharmaceutical Benefits Advisory Committee. The amendment was enacted by the Australian Parliament and is compatible with human rights, as it aligns with the International Covenant on Economic, Social and Cultural Rights by facilitating access to affordable medications. This determination is designed to reflect changes recommended by the independent Pharmaceutical Benefits Advisory Committee, which consults with various stakeholders including consumers, health professionals, and pharmaceutical companies. The amendment commenced on 1 September 2014 and is a legislative instrument under the Legislative Instruments Act 2003.

Scope and Application

The National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 8) applies to the conditions under which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. The scope of this legislation encompasses entities such as pharmacists and medical practitioners who are approved to supply pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS). The PBS is a Commonwealth-funded program that aims to provide affordable access to a wide range of medicines for all Australians. The Amendment Determination reflects changes made by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2014 (No. 9) and removes the drug omeprazole and clarithromycin and amoxycillin from Schedule 4 of the Principal Determination, which had previously been listed. This Amendment Determination operates on a national level and is intended to ensure that the Pharmaceutical Benefits Scheme remains up-to-date and effective in providing Australians with access to necessary medications. The Amendment Determination does not explicitly outline any exclusions, exemptions, or thresholds, but rather adjusts the conditions and listings to maintain the efficacy of the PBS. The application of the Act can be extended or restricted through subordinate instruments, as noted in the explanatory statement.

Key Provisions

The primary sections of the National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 8) (PB 62 of 2014) pertain to changes in the conditions governing payments made by the Commonwealth for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners. This Amendment Determination, effective from 1 September 2014, modifies the Principal Determination (PB 119 of 2008) under the National Health Act 1953 (the Act) to reflect updates in the Pharmaceutical Benefits Scheme (PBS). Specifically, it removes certain medications from Schedule 4 of the Principal Instrument, which lists the drugs eligible for Commonwealth payments. The obligations and requirements imposed by this Amendment Determination primarily revolve around the conditions that must be met for payments to be made by the Commonwealth for pharmaceutical benefits. These conditions include the necessity for pharmacists and medical practitioners to be approved under the Act, ensuring that the supply of pharmaceutical benefits adheres to the specified criteria. Furthermore, the determination underscores the role of the Pharmaceutical Benefits Advisory Committee (PBAC) in recommending changes to the Minister, who ultimately determines the conditions under which these payments will be made. The removal of certain drugs from the list of eligible pharmaceutical benefits signifies a shift in the scope of the PBS, impacting which medications will be subsidised by the Commonwealth. In terms of consequences for breach, the Act does not explicitly detail offences, penalties, or civil/criminal consequences within the Amendment Determination itself. However, any non-compliance with the conditions stipulated in the Principal Determination or this Amendment Determination could potentially lead to the withholding of payments or other administrative actions taken by the Commonwealth. The overarching legal framework of the National Health Act 1953 provides the basis for enforcement actions, though the specific penalties or consequences for breaches would depend on the nature and severity of the non-compliance. The determination's alignment with human rights, particularly the right to the highest attainable standard of physical and mental health as recognised in the International Covenant on Economic, Social and Cultural Rights (ICESCR), underscores the importance of adhering to these conditions to ensure the continued provision of affordable and timely access to essential medications. The Amendment Determination, by refining the conditions for Commonwealth payments, aims to maintain the integrity and effectiveness of the PBS. This legislative update reflects ongoing evaluations and recommendations by the PBAC, ensuring that the PBS remains responsive to public health needs and evidence-based practices. The compatibility with human rights, particularly the right to health, highlights the determination's role in progressively realising this fundamental human right through the provision of subsidised access to medicines. Overall, this Amendment Determination is a critical component in the ongoing management and evolution of the PBS within the Australian healthcare system.